Sanofi (SNY)
| Market Cap | 119.69B |
| Revenue (ttm) | 54.03B |
| Net Income (ttm) | 5.03B |
| Shares Out | 1.25B |
| EPS (ttm) | 4.00 |
| PE Ratio | 23.82 |
| Forward PE | 10.92 |
| Dividend | $2.04 (4.26%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 1,253,580 |
| Open | 47.95 |
| Previous Close | 48.00 |
| Day's Range | 47.61 - 48.03 |
| 52-Week Range | 45.22 - 58.97 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 57.50 (+20.34%) |
| Earnings Date | Oct 25, 2024 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is $57.5, which is an increase of 20.34% from the latest price.
News
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with ...
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indicatio...
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big phar...
The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the World
BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multip...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on D...
SandboxAQ CEO on the firm's partnership with Sanofi
Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.
Sanofi Cancels Consumer Healthcare Business Spin-Off
On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive negotiations ...
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead invest...
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - ...
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.
Sanofi Earnings Boosted by Early Vaccine Sales
The pharmaceutical company reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines an...
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved wel...
Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale
Sanofi moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks for a deal that values the business at $17.4 bill...
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant...
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
France will take a stake in Sanofi 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. priv...
PAI Partners makes higher offer for Sanofi's Opella, says Le Monde
French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's consumer health business Opella, the Le Monde newspaper said on Thursday, as PAI seeks to outbid U.S. rival Clayt...
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targete...
FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals
US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gyneco...